Breaking News

Allergan Acquires SkinMedica

November 16, 2012

Expands facial aesthetics business

Allergan, Inc. has entered into a definitive agreement to acquire SkinMedica, Inc. for $350 million up-front and an additional $25 million based on sales targets for acquired products. The acquisition includes SkinMedica’s topical aesthetics skin care business, which includes a variety of physician dispensed non-prescription aesthetic skin care products and prescription products.
Allergan plans to operate SkinMedica as a separate global business. Bob Rhatigan, who currently serves as senior vice president of Facial Aesthetics at Allergan, will assume the role of senior vice president, general manager and chief executive officer, SkinMedica. Mary Fisher, chief executive officer of SkinMedica, will join Allergan and assist Mr. Rhatigan in the acquisition integration to ensure revenue building opportunities.
“Allergan is widely recognized for our leadership in the facial aesthetics area,” said David E.I. Pyott, chairman of the board, president and chief executive officer, Allergan. “The acquisition of SkinMedica will nicely complement our existing facial aesthetics business, and will enable us to take a leadership position in the growing 'physician dispensed' topical aesthetics skin care category. Most importantly, the acquisition will allow us to expand our product portfolio to better meet the needs of our existing base of physician customers and their patients.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks